Development and clinical evaluation of the CapScan gastrointestinal sampling device for metabolomics monitoring

项目摘要 本项目的目标是开发CapScan胃肠道(GI)采样胶囊，并利用 这一设备可以促进我们对胃肠道疾病的理解。CapScan是一种新型的可食用设备 有可能定期收集和分析胃肠道的微生物区系，包括代谢 肠道微生物对食品的转化。我们将进行开发、台架测试和安全性评估， CapScan设备在健康志愿者身上的重复性和区域特异性。然后，我们将利用 CapScan设备在另外两项研究中测试质子泵抑制剂(PPI)对微生物组的影响 和代谢组，并测量小肠患者胃肠道的区域差异 抗生素治疗前后细菌过度生长(SIBO)情况。鉴于肠道对人类的中心地位 健康方面，CapScan技术可能会有更多的用途来监测一个人的健康， 最终使CapScan成为医学实践中的常规和信息来源，就像今天的血液测试一样。

Project Abstract The goal of this project is to develop the CapScan gastrointestinal (GI) tract sampling capsule, and to utilize this device to advance our understanding of gastrointestinal disorders. CapScan is a novel ingestible device with the potential to routinely collect and analyze the microbiota of the GI tract, including the metabolic transformation of food products by gut microbes. We will develop, bench test and assess the safety, reproducibility, regional specificity of the CapScan device on healthy human volunteers. We will then utilize the CapScan device in two additional studies to test the effect of a proton pump inhibitor (PPI) on the microbiome and metabolome and to measure the regional differences in the GI tract in patients with small intestinal bacterial overgrowth (SIBO) before and after antibiotic treatment. Given the centrality of the gut to human health, there will likely be additional uses of the CapScan technology in monitoring a person's health, eventually making CapScan as routine and informative in the practice of medicine as a blood test is today.